Patients with platinum-resistant ovarian cancer were randomly assigned to chemotherapy alone (CT) or with bevacizumab (BEV-CT). PROs were assessed using the European Organisation for Research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results